Эта страница была переведена автоматически, точность перевода не гарантируется. Пожалуйста, обратитесь к английской версии для исходного текста.

ACT001 для лечения диффузных внутренних понтиновых глиомов и H3K27-измененных высококачественных глиомов высокой степени

13 ноября 2026 г. обновлено: Nationwide Children's Hospital

Фаза II Исследование ACT001 у детей и подростков с диффузными внутренними глиомами понтины и высококлассными глиомами, изменяемыми H3K27

This is a Phase II open-label study to investigate the safety and efficacy of ACT001 in patients with DIPG and H3K27-altered HGG.

Обзор исследования

Подробное описание

Patients will be enrolled on either Cohort A for newly diagnosed DIPG or on Cohort B [ENROLLMENT PAUSED] for those with progressive / refractory DIPG or progressive / recurrent / refractory H3K27-altered HGG. Each cohort will receive ACT001 at 875 mg/m2 orally BID for 28 days (1 cycle of treatment), up to a maximum dose of 1700 mg BID. If patients are experiencing clinical benefit from study therapy, they will continue to receive ACT001 in repeat 28-day cycles for up to 26 cycles (approximately 2 years) or until disease progression, whichever occurs first. Continuation of treatment beyond 26 cycles may be considered if patients are receiving clinical benefit from the study, at the discretion of the sponsor and treating physician.

Тип исследования

Интервенционный

Регистрация (Оцененный)

60

Фаза

  • Фаза 2

Контакты и местонахождение

В этом разделе приведены контактные данные лиц, проводящих исследование, и информация о том, где проводится это исследование.

Контакты исследования

Места учебы

    • New South Wales
      • Randwick, New South Wales, Австралия, 2031
        • Рекрутинг
        • Sydney Children's Hospital
        • Контакт:
          • David Ziegler, MBBS, BSc, MD, PhD, FRACP
          • Номер телефона: 612 9382 1730
          • Электронная почта: d.ziegler@unsw.edu.au
    • Queensland
      • South Brisbane, Queensland, Австралия, 4101
        • Еще не набирают
        • Queensland Children's Hospital
        • Контакт:
    • Victoria
      • Melbourne, Victoria, Австралия, 3052
        • Еще не набирают
        • Royal Children's Hospital
        • Контакт:
    • Western Australia
      • Perth, Western Australia, Австралия, 6000
        • Еще не набирают
        • Perth Children's Hospital
        • Контакт:
    • Baden-Wurttemberg
      • Heidelberg, Baden-Wurttemberg, Германия, 69120
        • Еще не набирают
        • Hopp Children's Cancer Center at NCT Heidelberg (KiTZ)
        • Контакт:
    • Ontario
      • Toronto, Ontario, Канада, M5G1X8
        • Рекрутинг
        • The Hospital for Sick Children (SickKids)
        • Контакт:
          • Anirban Das, MD
          • Номер телефона: 429907 416-813-7654
          • Электронная почта: anirban.das@sickkids.ca
    • Quebec
      • Montreal, Quebec, Канада, H4A3J1
        • Еще не набирают
        • Montreal Children's Hospital
        • Контакт:
    • Grafton
      • Auckland, Grafton, Новая Зеландия, 1023
        • Еще не набирают
        • Starship Children's Hospital
        • Контакт:
          • Sarah Hunter, MB ChB
          • Номер телефона: +64 9 367 0000
          • Электронная почта: SHunter@adhb.govt.nz
    • Colorado
      • Aurora, Colorado, Соединенные Штаты, 80045
        • Рекрутинг
        • Children's Hospital Colorado
        • Контакт:
    • District of Columbia
      • Washington D.C., District of Columbia, Соединенные Штаты, 20010
        • Рекрутинг
        • Children's National Medical Center
        • Контакт:
    • Florida
      • Miami, Florida, Соединенные Штаты, 33155
        • Еще не набирают
        • Nicklaus Children's Hospital
        • Контакт:
    • Georgia
      • Atlanta, Georgia, Соединенные Штаты, 30322
        • Еще не набирают
        • Emory University/Children's Healthcare of Atlanta
        • Контакт:
    • Michigan
      • Ann Arbor, Michigan, Соединенные Штаты, 48109
        • Рекрутинг
        • C.S. Mott Children's Hospital
        • Контакт:
          • Santhosh Upadhyaya, MBBS
          • Номер телефона: 734-647-8902
          • Электронная почта: saupadhy@med.umich.edu
        • Контакт:
          • Carl Koschmann, MD
          • Номер телефона: 734-647-8902
          • Электронная почта: ckoschma@med.umich.edu
    • Missouri
      • St Louis, Missouri, Соединенные Штаты, 63110
        • Рекрутинг
        • St. Louis Children's Hospital
        • Контакт:
        • Контакт:
          • Michael Huang, MD
          • Номер телефона: 314-454-6018
          • Электронная почта: huangm@wustl.edu
    • North Carolina
      • Durham, North Carolina, Соединенные Штаты, 27708
        • Еще не набирают
        • Duke University Medical Center
        • Контакт:
          • Daniel Landi, MD
          • Номер телефона: 919-684-2410
          • Электронная почта: daniel.landi@duke.edu
    • Ohio
      • Cincinnati, Ohio, Соединенные Штаты, 45229
        • Рекрутинг
        • Cincinnati Children's Hospital
        • Контакт:
          • Peter de Blank, MD
          • Номер телефона: 513-517-2068
          • Электронная почта: Peter.deBlank@cchmc.org
      • Columbus, Ohio, Соединенные Штаты, 43235
        • Рекрутинг
        • Nationwide Children's Hospital
        • Контакт:
    • Pennsylvania
      • Philidelphia, Pennsylvania, Соединенные Штаты, 19104
        • Еще не набирают
        • Children's Hospital of Philidelphia
        • Контакт:
          • MIchael J Fisher, MD
          • Номер телефона: 215-590-5188
          • Электронная почта: fisherm@email.chop.edu
    • Texas
      • Houston, Texas, Соединенные Штаты, 77030
        • Рекрутинг
        • Texas Children's Hospital
        • Контакт:
          • Patricia Baxter, MD
          • Номер телефона: 832-824-4681
          • Электронная почта: pabaxter@txch.org
    • Washington
      • Seattle, Washington, Соединенные Штаты, 98105
        • Рекрутинг
        • Seattle Children's Hospital
        • Контакт:

Критерии участия

Исследователи ищут людей, которые соответствуют определенному описанию, называемому критериям приемлемости. Некоторыми примерами этих критериев являются общее состояние здоровья человека или предшествующее лечение.

Критерии приемлемости

Возраст, подходящий для обучения

От 1 год до 39 лет (Ребенок, Взрослый)

Принимает здоровых добровольцев

Нет

Полы, имеющие право на обучение

Все

Описание

Inclusion Criteria:

  1. Patients must be ≥ 12 months and ≤ 39 years of age at the time of study enrollment.

  2. Diagnosis:

    • Cohort A: Newly Diagnosed DIPG

      • Patients with newly-diagnosed DIPG with typical MRI findings (tumors with a pontine epicenter and diffuse involvement of at least 2/3 of the pons) with or without biopsy and have completed radiation therapy (RT) within 28 to 35 calendar day prior to start of therapy.

      • Patients must have started RT <42 calendar days from radiographic diagnosis (for non-biopsied DIPG patients only) or definitive surgery, whichever is later.

        • If a biopsy was performed, the date of surgical biopsy will be considered the date of definitive diagnostic surgery; if a patient underwent two upfront surgeries [e.g., biopsy then debulking], this is the date of the second surgery)
    • Cohort B [ENROLLMENT PAUSED]: progressive/recurrent DIPG or H3K27-altered HGG OR refractory disease

      • Patients with DIPG (no biopsy required), pathologically-confirmed (at diagnosis or recurrence) H3K27-altered DIPG, or extra-pontine H3K27-alteredHGG who have progressive/recurrent or refractory disease
      • Progressive/recurrent: patients who have progressive or recurrent disease following frontline treatment must have included at least focal RT. New lesions since completion of frontline RT qualify as progressive disease.
      • Refractory disease is defined as: Presence of persistent, measurable, abnormality on conventional MRI that is further distinguished by histology or advanced imaging, OR as determined by the treating physician and discussed with the Study Chair(s) prior to enrollment.
      • Patients with H3K27-altered spinal HGG are eligible.
      • Patients with metastatic disease are eligible.
  3. Disease Status

    • Cohort A: patients may have any disease status but must have completed initial radiation therapy (RT) before enrollment.
    • Cohort B: Patients must have measurable disease assessable by MRI. Patients may have extra neuronal disease.
  4. Performance Level: Karnofsky Performance Scale score ≥ 50% for patients > 16 years of age and Lansky Performance Scale score > 50% for patients ≤ 16 years of age (applies to all patients) Note: Patients who are unable to walk because of paralysis, but who are capable of using a wheelchair, will be considered ambulatory for the purpose of assessing the performance score.

  5. Prior anti-cancer therapy:

    • For Cohort A ONLY:
    • Surgery, radiation (focal to disease) and/or steroids (dexamethasone with goal to wean dexamethasone throughout protocol therapy) are permissible. Temozolomide administered concurrently with RT is permissible. Bevacizumab use is permitted given the last dose was administered >/= 21 days prior to enrollment. No other prior anticancer therapy for DIPG will be allowed.
    • Patients must enroll and start treatment on study between 28 and 35 calendar days post-completion of RT.
    • Patients must have started RT <42 calendar days of initial diagnosis (defined as the date of diagnostic biopsy or resection; if a patient underwent two upfront surgeries [e.g., biopsy then resection or debulking], this is the date of the second surgery).
    • Radiotherapy must have been administered at standard dose of 54 Gy for DIPG patients. Any variances in the radiotherapy dose within 10% of the standard doses outlined above will be discussed with the Study Chair to confirm eligibility prior to study enrollment.
    • For Cohort B ONLY: Patients must have fully recovered from the acute treatment related toxicities (defined as </= Grade 1 if not defined in eligibility criteria) of all prior chemotherapy, immunotherapy, radiotherapy, or any other treatment modality prior to entering on this study, with the exception of alopecia.

    Notes to the above for Cohort B: Patients with chronic Grade 2 toxicities may be eligible per discretion of the Investigator and Sponsor (e.g., Grade 2 chemotherapy-induced neuropathy). Grade 2 or 3 toxicities from prior anti-tumor therapy that are considered irreversible - defined as having been present and stable for > 6 months (such as ifosfamide-related proteinuria) may be allowed if they are not otherwise described in the exclusion criteria AND there is agreement to allow by both the Investigator and Sponsor.)

    The wash out period between the prior anti-cancer chemotherapy, and enrollment must be:

    1. Myelosuppressive chemotherapy: At least 21 days after the last dose of myelosuppressive chemotherapy (42 days if prior nitrosourea).

    2. Hematopoietic growth factors: At least 14 days after the last dose of a long-acting growth factor (e.g. Neulasta) or 7 days for short-acting growth factor.

    3. Biologic (anti-neoplastic agent): At least 7 days after the last dose of a biologic agent. For agents that have known adverse events occurring beyond 7 days after administration, this period must be extended beyond the time during which adverse events are known to occur. The duration of this interval must be discussed with the study chair.

    4. Immunotherapy: At least 42 days after the completion of any type of immunotherapy, e.g. tumor vaccines.

    5. Monoclonal antibodies: > 21 days must have elapsed from the infusion of last dose of antibody

    6. Radiation therapy:

      • All Cohort B patients: Patients must have received their last fraction of focal irradiation to new sites of progressive disease > 14 days prior to enrollment.

        • Patients who received CSI must have received their last fraction > 3 months prior to enrollment.
      • Progressive/recurrent disease: Patients who received re-irradiation to primary disease must have received their last fraction > 3 months prior to study enrollment.

      • Refractory Disease:

        • Patients must have completed frontline RT > 6 months prior to enrollment.
        • Patients who received re-irradiation to primary disease must have received their last fraction > 3 months prior to study enrollment.
    7. Stem Cell Transplant: Patients must be ≥ 3 months since autologous stem cell transplant. Patients who received allogenic stem cell transplant or solid organ transplant are not eligible for study

  6. Organ Function Requirements (applies to all patients)

    1. Adequate bone marrow function defined as:

      • Peripheral absolute neutrophil count (ANC) > 1000/mm³
      • Platelet count > 100,000/mm³ (transfusion independent, defined as not receiving platelet transfusions for at least 7 days prior to enrollment)
    2. Adequate renal function defined as:

      • Creatinine clearance or radioisotope GFR ≥ 70 mL/min/1.73 m² or
      • A serum creatinine based on age/gender as follows (Schwartz et al. J. Peds, 106:522, 1985): Age Maximum Serum Creatinine (mg/dL) Male Female 1 to < 2 years 0.6 0.6 2 to < 6 years 0.8 0.8 6 to < 10 years 1.0 1.0 10 to < 13 years 1.2 1.2 13 to < 16 years 1.5 1.4 ≥ 16 years 1.7 1.4
    3. Adequate liver function defined as:

      • total bilirubin must be </=1.5X institutional ULN for age
      • AST (serum glutamic-oxaloacetic transaminase [SGOT]) / ALT (serum glutamic-oxaloacetic transaminase [SGPT]) ≤ 2.5 × institutional upper limit of normal
      • Serum albumin ≥ 2 g/dL
    4. Adequate cardiac function defined as:

      • Ejection fraction of ≥ 50% by echocardiogram
      • QTc ≤ 450 msec (by Bazett formula)
    5. For Cohort B: Adequate neurologic function defined as:

      • Patients with seizure disorders may be enrolled if seizures are well- controlled. Well controlled is defined by no increase in seizure frequency in the 7 days prior to enrollment.
      • Patients with neurological deficits should have deficits that are stable for at least the 7 days prior to enrollment.
  7. Informed Consent: All patients and/or their parents or legally authorized representatives must sign a written informed consent. Assent, when appropriate, will be obtained according to institutional guidelines.

  8. Absence of other clinically significant concomitant active medical disorder, based on the investigator's judgement.

Exclusion Criteria:

A patient who meets any of the following exclusion criteria will not be eligible in the study (Applies to both cohorts except where noted below):

  1. Cohort A only: Patients with metastatic disease.

  2. Concomitant medications:

    • Corticosteroids:

      • Cohort A - Patients receiving corticosteroids are eligible regardless of dosing
      • Cohort B - Patients receiving corticosteroids who have been on a stable or decreasing dose of corticosteroid for at least 7 days prior to enrollment are eligible
    • Anti-cancer Agents: Patients who are currently receiving other anti-cancer agents are not eligible (Refer study inclusion criteria relating to anti-cancer therapies)

      • Cohort A - Patients that have received any anti-cancer treatment other than surgery, RT, temozolomide concurrent with RT, and/or previous bevacizumab with appropriate washout period are not eligible.
    • Investigational Drugs: Patients who are currently receiving another investigational drug are not eligible.

    • Anticonvulsants should be used as clinically indicated. The use of enzyme inducing anticonvulsants is not permitted

    • LHRH agonist / antagonists are not permitted

    • High Dose Biotin (B7) supplements are not permitted

  3. Concomitant medications used with caution: selective serotonin reuptake inhibitor (SSRI) such as Lexapro, Fluoxetine (Prozac), fluvoxamine (Luvox), paroxetine (Paxil), sertraline (Zoloft), citalopram (Celexa), and escitalopram should be used with caution.

  4. Infection: Patients who currently have an uncontrolled infection (in the opinion of the PI) are not eligible.

  5. Patients who have received a prior solid organ transplantation are not eligible.

  6. Pregnant or breast-feeding women will not be entered on this study due to unknown risks of fetal and teratogenic adverse events as seen in animal/human studies. Pregnancy tests must be obtained in girls who are postmenarchal. Males or females of reproductive potential may not participate unless they have agreed to use an effective contraceptive method.

  7. Patients of childbearing or child fathering potential must agree to use adequate contraceptive methods (hormonal or barrier method of birth control; abstinence) while being treated on this study and for 3 months after completing therapy. Note: The definition of effective contraception will be based on the judgement of the principal investigator or a designated associate.

  8. Patients who are in the opinion of the investigator may not be able to comply with the safety monitoring requirements of the study are not eligible.

  9. Patients who have previously received either ACT001 or parthenolide are not eligible.

Учебный план

В этом разделе представлена ​​подробная информация о плане исследования, в том числе о том, как планируется исследование и что оно измеряет.

Как устроено исследование?

Детали дизайна

  • Основная цель: Уход
  • Распределение: Нерандомизированный
  • Интервенционная модель: Одногрупповое задание
  • Маскировка: Нет (открытая этикетка)

Оружие и интервенции

Группа участников / Армия
Вмешательство/лечение
Экспериментальный: Cohort A

Patients with newly-diagnosed DIPG with typical MRI findings

PO BID at 875 mg/m2 for 28 days

Экспериментальный: Cohort B [ENROLLMENT PAUSED]

Patients with progressive/recurrent DIPG or H3K27-altered HGG OR refractory disease

PO BID at 875 mg/m2 for 28 days

Что измеряет исследование?

Первичные показатели результатов

Мера результата
Мера Описание
Временное ограничение
Overall Survival (OS) for newly diagnosed DIPG
Временное ограничение: From date on treatment until date of death due to any cause or date of last follow-up, assessed up to 60 months

To assess the overall survival for newly-diagnosed patients with DIPG treated with RT followed by ACT001.

From date on treatment until date of death due to any cause or date of last follow-up, assessed up to 60 months
Objective Response Rate (ORR) in Progressive/Refractory/Recurrent HGG after frontline RT
Временное ограничение: Date on treatment through 30 days following end of protocol treatment

To assess the rate of objective response rate (defined as partial response + complete response) in patients who have been treated with at least frontline focal RT and have progressive DIPG or progressive/recurrent/refractory H3K27-altered HGG who are treated with ACT001

Date on treatment through 30 days following end of protocol treatment

Вторичные показатели результатов

Мера результата
Мера Описание
Временное ограничение
Overall Survival in Progressive/Refractory/Recurrent DIPG and H3K27-altered DIPG
Временное ограничение: From date on treatment until date of death due to any cause or date of last follow-up, assessed up to 60 months

To estimate the overall survival and duration of disease control for patients who have been treated with at least RT and have progressive DIPG or progressive/recurrent/refractory H3K27-altered HGG who are treated with ACT001

From date on treatment until date of death due to any cause or date of last follow-up, assessed up to 60 months

Соавторы и исследователи

Здесь вы найдете людей и организации, участвующие в этом исследовании.

Соавторы

Следователи

  • Учебный стул: David S. Ziegler, MD, FRACP, Sydney Children's Hospitals Network
  • Учебный стул: Sara Khan, MD, PhD, FRACP, Nationwide Children's Hospital
  • Учебный стул: Peter de Blank, MD, MSCE, Children's Hospital Medical Center, Cincinnati

Даты записи исследования

Эти даты отслеживают ход отправки отчетов об исследованиях и сводных результатов на сайт ClinicalTrials.gov. Записи исследований и сообщаемые результаты проверяются Национальной медицинской библиотекой (NLM), чтобы убедиться, что они соответствуют определенным стандартам контроля качества, прежде чем публиковать их на общедоступном веб-сайте.

Изучение основных дат

Начало исследования (Действительный)

10 июля 2025 г.

Первичное завершение (Оцененный)

1 июля 2028 г.

Завершение исследования (Оцененный)

1 июля 2035 г.

Даты регистрации исследования

Первый отправленный

19 февраля 2025 г.

Впервые представлено, что соответствует критериям контроля качества

19 февраля 2025 г.

Первый опубликованный (Действительный)

21 февраля 2025 г.

Обновления учебных записей

Последнее опубликованное обновление (Действительный)

17 ноября 2026 г.

Последнее отправленное обновление, отвечающее критериям контроля качества

13 ноября 2026 г.

Последняя проверка

1 ноября 2026 г.

Дополнительная информация

Термины, связанные с этим исследованием

Планирование данных отдельных участников (IPD)

Планируете делиться данными об отдельных участниках (IPD)?

НЕТ

Информация о лекарствах и устройствах, исследовательские документы

Изучает лекарственный продукт, регулируемый FDA США.

Да

Изучает продукт устройства, регулируемый Управлением по санитарному надзору за качеством пищевых продуктов и медикаментов США.

Нет

Эта информация была получена непосредственно с веб-сайта clinicaltrials.gov без каких-либо изменений. Если у вас есть запросы на изменение, удаление или обновление сведений об исследовании, обращайтесь по адресу register@clinicaltrials.gov. Как только изменение будет реализовано на clinicaltrials.gov, оно будет автоматически обновлено и на нашем веб-сайте. .

Подписаться